Sponsors / ALT
ALT

Altimmune, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
6Trials in this database
18Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAXNCT03232567ALTPhase 2Completed2018-03-07Actual
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)NCT04684914ALTPhase 2Terminated2024-03-27Actual
Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875ALTPhase 2Completed2023-09-28Actual
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05989711ALTPhase 2Completed2025-11-25Actual
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513ALTPhase 2Completed2026-07-30Actual
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860ALTPhase 2Active not recruiting2027-09-30Estimated

Latest recorded trial changes

RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

NCT07009860 · Altimmune, Inc.

· 5 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Relative (%) change in liver stiffness by VCTE compared to baseline at Week 24

+ Updated value

measure: Relative (%) reduction in liver stiffness by VCTE compared to baseline

The saved outcome text may be shortened. Check the source for full wording.

Participant count type

Recorded edit
− Previous value

Estimated

+ Updated value

Actual

Enrollment · participant count

Recorded edit
− Previous value

count: 100; type: ESTIMATED

+ Updated value

count: 121; type: ACTUAL

Primary completion date

Recorded edit
− Previous value

2027-03-31

+ Updated value

2027-09-30

Recruitment status

Recorded edit
− Previous value

Recruiting

+ Updated value

Active not recruiting

Check registry source
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

NCT06987513 · Altimmune, Inc.

· 4 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Change from baseline in the average number of heavy drinking days per week, with a heavy drinking day defined as 5 or more drinks in the day for men and 4 or more drinks in the day for women, using the TLFB method

+ Updated value

measure: Change from baseline in the average number of heavy drinking days per week

The saved outcome text may be shortened. Check the source for full wording.

Completion date type

Recorded edit
− Previous value

Estimated

+ Updated value

Actual

Primary completion date

Recorded edit
− Previous value

2026-05

+ Updated value

2026-07-30

Recruitment status

Recorded edit
− Previous value

Active not recruiting

+ Updated value

Completed

Check registry source
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT05989711 · Altimmune, Inc.

· 2 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis; measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis)

+ Updated value

measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis; measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis); measure: Incidence of Treatment Emergent Adverse Events

The saved outcome text may be shortened. Check the source for full wording.

Primary completion date

Recorded edit
− Previous value

2025-04-29

+ Updated value

2025-11-25

Check registry source
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

NCT06987513 · Altimmune, Inc.

· 3 fields changed

Participant count type

Recorded edit
− Previous value

Estimated

+ Updated value

Actual

Primary completion date

Recorded edit
− Previous value

2026-09-30

+ Updated value

2026-05

Recruitment status

Recorded edit
− Previous value

Recruiting

+ Updated value

Active not recruiting

Check registry source